Adlai NortyeANL
Market Cap: 129M
About: Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Employees: 127
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 3 [Q4 2023] → 3 (+0) [Q1 2024]
0% less ownership
Funds ownership: 0.07% [Q4 2023] → 0.06% (-0%) [Q1 2024]
8% less capital invested
Capital invested by funds: $560K [Q4 2023] → $514K (-$45.5K) [Q1 2024]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for ANL.